Bridgeway Capital Management’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
Bridgeway Capital Management's TRDA Position: Q3 2026 in Review
Bridgeway Capital Management increased its Entrada Therapeutics (TRDA) stake by 78% in Q3 2026, buying an estimated $135K and bringing the position to 44,513 shares worth $283K. The position accounts for 0.01% of the portfolio, ranked #934.
Bridgeway Capital Management first reported a position in TRDA in Q3 2025 and has held it in 5 quarters since. The position peaked at $411K in Q4 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- Bridgeway Capital Management held 44,513 shares of Entrada Therapeutics worth $283K as of Q3 2026.
- Bridgeway Capital Management bought 19,513 Entrada Therapeutics shares in Q3 2026, an estimated $135K.
- Entrada Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #934 holding.
- Bridgeway Capital Management first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Bridgeway Capital Management's Entrada Therapeutics position peaked at $411K in Q4 2025.
- 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.